Since the final participant for this MAPP2 was treated on November 17, 2022, the database has been locked and is being analyzed. This study is our second Phase 3 trial of MDMA-assisted therapy for posttraumatic stress disorder and the results are expected to be announced in the New Year. The MAPP2 data will be part of the new drug application that MAPS PBC plans to submit in 2023.